80
Participants
Start Date
December 3, 2018
Primary Completion Date
July 31, 2019
Study Completion Date
August 28, 2019
Vortioxetine infusion 25 mg
1 mg/mL, concentrate for solution for infusion, 25 mL (25 mg) administered in 250 mL saline over 2 hours as single dose for 7 days
Vortioxetine tablets 10 mg/day
10 mg, tablets, oral administration once daily
Placebo infusion
concentrate for solution for infusion, 25 mL administered in 250 mL saline over 2 hours as single dose
Placebo tablets
oral administration once daily
Mental Health Centre 'Prof. Dr. Ivan Temkov', EOOD (BG1004), Burgas
SPH - Kardzhali, EOOD (BG1005), Kardzhali
"MHAT Dr. Hristo Stambolski, EOOD (BG1001)", Kazanlak
"State Psychiatric Hospital Sv. Ivan Rilski (BG1009)", Novi Iskar
UMHAT 'Dr. Georgi Stranski', EAD (BG1006), Pleven
MHC - Ruse, EOOD (BG1007), Rousse
State Psychiatric Hospital (BG1008), Tsarev Brod
Mental Health Center-Vratsa EOOD (BG1002), Vratsa
Marienthali Kliinik (EE2001), Tallinn
Tartu University Hospital (EE2002), Tartu
Psychoneurological Hospital of Daugavpils (LV3003), Daugavpils
Riga Centre of Psychiatry and Narcology (LV3002), Riga
Psychoneurological Hospital of Strenci (LV3001), Strenči
H. Lundbeck A/S
INDUSTRY